If you or someone you know has taken Reglan and noticed unusual facial or body movements, you may be wondering about tardive dyskinesia. Decades of pharmacovigilance research have firmly established that prolonged use of metoclopramide can lead to this often-irreversible movement disorder. This page explains the early signs, screening recommendations, and how exposure history—including occupational contact—factors into risk assessment.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. Its mechanism of action can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents, a category that includes metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is associated with increased comorbidities, social stigmatization, and impaired physical and mental health, and it tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/). The risk of developing TD from Reglan increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, a total duration of treatment longer than 12 weeks should be avoided; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug should be used for the shortest duration of treatment, and the need for continued treatment should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The timeline between exposure to Reglan and documented harm can vary. While TD is often associated with longer-term use, cases have been reported after a single dose. For example, a case report describes a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This patient was found to have several risk factors for TD, highlighting that individual susceptibility plays a role. Older age is associated with increased risk of TD and with the emergence of TD occurring after shorter treatment durations and lower dosages of dopamine receptor-blocking agents (https://pubmed.ncbi.nlm.nih.gov/34703232/). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings regarding Reglan and TD is addressed in the prescribing information. The label includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning also notes that the risk increases with duration of treatment and total cumulative dosage, that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, the warnings and precautions section reiterates that metoclopramide can cause TD and advises avoiding concomitant use of other drugs known to cause TD, as well as avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, the occurrence of TD after short-term or even single-dose use, as documented in case reports, suggests that clinicians and patients should remain vigilant even with limited exposure.
For affected patients, causation-related considerations include the established link between Reglan and TD, the dose-response relationship, and the potential for irreversible harm. The presence of risk factors such as older age may increase susceptibility. The timeline between exposure and harm can range from days to years, but even a single dose has been associated with TD in susceptible individuals. Patients who develop TD after Reglan use should be aware that the condition may persist despite discontinuation of the drug. The prescribing information emphasizes immediate discontinuation if symptoms occur and seeking medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Given the potentially irreversible nature of TD, the adequacy of warnings and the need for careful risk-benefit assessment before initiating Reglan therapy are critical.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary movements of the face, tongue, trunk, or extremities. The risk increases with longer treatment duration and higher cumulative doses, but cases have been reported even after a single dose. (https://pubmed.ncbi.nlm.nih.gov/34712535/) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397)
Yes, although TD is more common with long-term use, there are documented cases of TD developing after short-term or even single-dose administration of metoclopramide. Individual susceptibility, such as older age or other risk factors, may play a role. (https://pubmed.ncbi.nlm.nih.gov/34712535/)
If you experience any signs or symptoms of TD, such as involuntary movements, you should immediately discontinue Reglan and seek medical attention. The prescribing information includes a boxed warning about this risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397)
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.